DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer.
|
Shape Divider - Style triangle
OUR TECHNOLOGYDepYmed is developing novel therapeutics targeting the role of protein tyrosine phosphatases in signaling pathways involved in the pathology of multiple diseases.
Advancing two orally bioavailable small molecules into clinical trials for: We are building a library of novel selective PTP1B (phosphatase) inhibitors with therapeutic potential for other major metabolic, inflammatory and neurodegenerative diseases. |
Shape Divider - Style triangle
Shape Divider - Style triangle
RECENT NEWS
DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome
By DepYmed, Inc. | March 19, 2024 DepYmed to Meet with Investors at the BIO CEO and Investor Conference
By DepYmed, Inc. | February 21, 2024 DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
By DepYmed, Inc. | February 7, 2024 DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023
By DepYmed, Inc. | October 3, 2023 DepYmed to Meet with Investors at the BioFuture Conference in New York City October 4-6, 2023
By DepYmed, Inc. | September 27, 2023 DepYmed to Meet with Investors at the LSX World Congress USA in Boston on September 13-14, 2023
By DepYmed, Inc. | September 7, 2023 DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
By DepYmed, Inc. | June 14, 2023 |
Shape Divider - Style triangle